Evidence map›Paper›PMID 41955504›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Nano-Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy.

Wenjing Zhou, Yuting Li, Xudong Sun, Honghong Yang, Xiayu Shi, Lijia Yao, Jinhong Jiang, Erli Wang, Haoyang Wang, Yi Wei and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenjing ZhouSchool of Life Sciences, Tianjin University, Tianjin, China.
Yuting LiZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Xudong SunFuyang Institute, Zhejiang Chinese Medical University, Hangzhou, China.
Honghong YangZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Xiayu ShiZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Lijia YaoZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Jinhong JiangZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Erli WangZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Haoyang WangZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Yi WeiZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Xiangsheng LiuZhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Basic and Clinical Application of Functional Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.ORCID https://orcid.org/0000-0002-5719-2838

Funding

National Natural Science Foundation of China 32201143National Natural Science Foundation of China 32471438Pioneer" and "Leading Goose" R&D Program of Zhejiang 2023SDYXS0001Pioneer" and "Leading Goose" R&D Program of Zhejiang 2024DYXS0001Zhejiang Provincial Natural Science Foundation of China LDQ24B020002
6 · The paper itself

Abstract

Activation of the STING pathway represents a potent strategy for cancer immunotherapy. However, the instability and systemic toxicity of STING agonists, especially cyclic dinucleotides (CDNs), limit their use via local administration with poor efficacy against metastatic or inaccessible tumors. Here, we develop an engineered silicasome nanocarrier for systemic delivery of the CDN ADU-S100 (ADU-Sili). Comprising ADU-S100-loaded mesoporous silica nanoparticles (MSNPs) coated with lipid bilayer, ADU-Sili markedly enhanced tumor accumulation and antitumor efficacy compared with free ADU-S100 and conventional liposomes in vivo. The advantage of systemic delivery was further demonstrated in bilateral tumors: ADU-Sili induced systemic antitumor immunity, suppressing both tumors, whereas free ADU-S100 inhibited only injected tumors. Immune profiling revealed that ADU-Sili promoted dendritic cell maturation in lymph nodes, expanded cytotoxic and memory CD8

Indexed as

ImmunotherapyMembrane ProteinsNanoparticlesNeoplasmsSilicon DioxideAnimalscGAS-STING Signaling PathwayFemaleHumansMiceSTING ProteinMembrane ProteinsSilicon DioxideSting1 protein, mouseSTING Proteincancer immunotherapycyclic dinucleotidesilicasome nanocarrierSTING agonistsystemic delivery

Identifiers

PMID41955504
PMCPMC13285114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.